BACKGROUND: Intensive chemotherapy for pediatric acute myeloid leukemia incurs the risk of infectious complications, but the benefits of antibiotic prophylaxis remain unclear. METHODS: In the current study, among 103 children treated on the AML02 protocol between October 2002 and October 2008 at St. Jude Children's Research Hospital, the authors retrospectively assessed the effect of antibiotic prophylaxis on the frequency of febrile neutropenia, clinically or microbiologically confirmed infections (including bacteremia), and antibiotic resistance, as well as on the results of nasal and rectal surveillance cultures. Initially, patients received no prophylaxis or oral cephalosporin (group A). The protocol was then amended to administer intravenous cefepime alone or intravenous vancomycin plus either oral cephalosporin, oral ciprofloxacin, or intravenous cefepime (group B). RESULTS: There were 334 infectious episodes. Patients in group A had a significantly greater frequency of documented infections and bacteremia (both P < .0001) (including gram-positive and gram-negative bacteremia; P = .0003 and .001, respectively) compared with patients in group B, especially viridans streptococcal bacteremia (P = .001). The incidence of febrile neutropenia without documented infection was not found to be different between the 2 groups. Five cases of bacteremia with vancomycin-resistant enterococci (VRE) occurred in group B (vs none in group A), without related mortality. Two of these cases were preceded by positive VRE rectal surveillance cultures. CONCLUSIONS: Outpatient intravenous antibiotic prophylaxis is feasible in children with acute myeloid leukemia and reduces the frequency of documented infection but not of febrile neutropenia. Despite the emergence of VRE bacteremia, the benefits favor antibiotic prophylaxis. Creative approaches to shorten the duration of prophylaxis and thereby minimize resistance should be explored.
BACKGROUND: Intensive chemotherapy for pediatric acute myeloid leukemia incurs the risk of infectious complications, but the benefits of antibiotic prophylaxis remain unclear. METHODS: In the current study, among 103 children treated on the AML02 protocol between October 2002 and October 2008 at St. Jude Children's Research Hospital, the authors retrospectively assessed the effect of antibiotic prophylaxis on the frequency of febrile neutropenia, clinically or microbiologically confirmed infections (including bacteremia), and antibiotic resistance, as well as on the results of nasal and rectal surveillance cultures. Initially, patients received no prophylaxis or oral cephalosporin (group A). The protocol was then amended to administer intravenous cefepime alone or intravenous vancomycin plus either oral cephalosporin, oral ciprofloxacin, or intravenous cefepime (group B). RESULTS: There were 334 infectious episodes. Patients in group A had a significantly greater frequency of documented infections and bacteremia (both P < .0001) (including gram-positive and gram-negative bacteremia; P = .0003 and .001, respectively) compared with patients in group B, especially viridans streptococcal bacteremia (P = .001). The incidence of febrile neutropenia without documented infection was not found to be different between the 2 groups. Five cases of bacteremia with vancomycin-resistant enterococci (VRE) occurred in group B (vs none in group A), without related mortality. Two of these cases were preceded by positive VRE rectal surveillance cultures. CONCLUSIONS:Outpatient intravenous antibiotic prophylaxis is feasible in children with acute myeloid leukemia and reduces the frequency of documented infection but not of febrile neutropenia. Despite the emergence of VRE bacteremia, the benefits favor antibiotic prophylaxis. Creative approaches to shorten the duration of prophylaxis and thereby minimize resistance should be explored.
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: Lillian Sung; Richard Aplenc; Theo Zaoutis; Andreas H Groll; Brenda Gibson; Thomas Lehrnbecher Journal: Pediatr Blood Cancer Date: 2008-10 Impact factor: 3.167
Authors: Carol O'Hear; Hiroto Inaba; Stanley Pounds; Lei Shi; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Ching-Hon Pui; Raul C Ribeiro; Elaine Coustan-Smith; Dario Campana; Jeffrey E Rubnitz Journal: Cancer Date: 2013-09-04 Impact factor: 6.860
Authors: Beth Kurt; Patricia Flynn; Jerry L Shenep; Stanley Pounds; Shelly Lensing; Raul C Ribeiro; Ching-Hon Pui; Bassem I Razzouk; Jeffrey E Rubnitz Journal: Cancer Date: 2008-07-15 Impact factor: 6.860
Authors: Aditya H Gaur; Mary Anne Giannini; Patricia M Flynn; Jan W Boudreaux; Mark A Mestemacher; Jerry L Shenep; Randall T Hayden Journal: Pediatr Infect Dis J Date: 2003-06 Impact factor: 2.129
Authors: Amanda Kosack; Elyn Riedel; Timothy E Kiehn; Trudy N Small; Leonard H Wexler; Ira J Dunkel Journal: Pediatr Blood Cancer Date: 2009-02 Impact factor: 3.838
Authors: H Inaba; D Pei; J Wolf; S C Howard; R T Hayden; M Go; O Varechtchouk; T Hahn; J Buaboonnam; M L Metzger; J E Rubnitz; R C Ribeiro; J T Sandlund; S Jeha; C Cheng; W E Evans; M V Relling; C-H Pui Journal: Ann Oncol Date: 2017-02-01 Impact factor: 32.976
Authors: Ditte J A Løhmann; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Minna Koskenvuo; Birgitte Lausen; Josefine Palle; Bernward Zeller; Henrik Hasle Journal: Haematologica Date: 2016-07-28 Impact factor: 9.941
Authors: Tamara P Miller; Kelly D Getz; Marko Kavcic; Yimei Li; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Marla Daves; Terzah M Horton; Michael A Pulsipher; Jessica Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Alan S Gamis; Richard Aplenc Journal: Leuk Lymphoma Date: 2016-01-04
Authors: Kelly D Getz; Yimei Li; Todd A Alonzo; Matthew Hall; Robert B Gerbing; Lillian Sung; Yuan-Shung Huang; Staci Arnold; Alix E Seif; Tamara P Miller; Rochelle Bagatell; Brian T Fisher; Peter C Adamson; Alan Gamis; Ron Keren; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2015-05-06 Impact factor: 3.167
Authors: Thomas B Alexander; Lei Wang; Hiroto Inaba; Brandon M Triplett; Stanley Pounds; Raul C Ribeiro; Ching-Hon Pui; Jeffrey E Rubnitz Journal: Cancer Date: 2017-05-30 Impact factor: 6.860
Authors: Romy E Van Weelderen; Kim Klein; Bianca F Goemans; Wim J E Tissing; Tom F W Wolfs; Gertjan J L Kaspers Journal: Cancers (Basel) Date: 2022-06-28 Impact factor: 6.575
Authors: Jason W Rosch; Joshua Wolf; Tina H Dao; Ramzi Alsallaq; Joshua B Parsons; Jose Ferrolino; Randall T Hayden; Jeffrey E Rubnitz; Iftekhar M Rafiqullah; D Ashley Robinson; Elisa B Margolis Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191
Authors: Sarah Alexander; Brian T Fisher; Aditya H Gaur; Christopher C Dvorak; Doojduen Villa Luna; Ha Dang; Lu Chen; Michael Green; Michael L Nieder; Beth Fisher; L Charles Bailey; John Wiernikowski; Lillian Sung Journal: JAMA Date: 2018-09-11 Impact factor: 56.272